Ergoteles’s GT Biopharma GTBP Stock Holding History

Ergoteles’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,703	Closed	-$242K	–	1712
2022 Q2	$242K	Buy	+2,703	New	+$205K	0.01%	1220

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ergoteles's GTBP Position: Q3 2022 in Review

Ergoteles sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 2,703 shares — an estimated $242K sold.

Ergoteles first reported a position in GTBP in Q2 2022 and held it in 1 quarter. The position peaked at $242K in Q2 2022. 34 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

Ergoteles reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 2,703 GT Biopharma shares in Q3 2022, an estimated $242K.
Ergoteles first reported a position in GT Biopharma in Q2 2022 and held it in 1 quarter.
Ergoteles's GT Biopharma position peaked at $242K in Q2 2022.
34 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.